The between team

Executives at the Department of Health and Human Services have named a few acting agency heads as the US government prepares to transition into a new administration under President-Elect Barack Obama. There are no real surprises, with deputies or second-in-commands taking over next week and serving at top spots until successors are named by incoming HHS head linkurl:Tom Daschle;http://www.the-scientist.com/blog/display/55206/ or directly by Obama. Cancer biologist linkurl:Frank Torti,;http://w

By | January 12, 2009

Executives at the Department of Health and Human Services have named a few acting agency heads as the US government prepares to transition into a new administration under President-Elect Barack Obama. There are no real surprises, with deputies or second-in-commands taking over next week and serving at top spots until successors are named by incoming HHS head linkurl:Tom Daschle;http://www.the-scientist.com/blog/display/55206/ or directly by Obama. Cancer biologist linkurl:Frank Torti,;http://www1.wfubmc.edu/canbio/Faculty/Torti+F.htm who spoke with __The Scientist__ last year when he was named the Food and Drug Administration's first ever Chief Scientist, will serve as FDA head starting on Inauguration Day, January 20th. You can hear a snippet of the conversation I had with Torti linkurl:here.;http://images.the-scientist.com/supplementary/audio/torti_cut.wav Other temporary assignments include linkurl:Raynard Kington;http://www.nih.gov/about/director/index.htm staying on as acting director of the National Institutes of Health, and Centers for Disease Control & Prevention chief operating officer linkurl:William Gimson;http://www.cdc.gov/about/leadership/leaders/gimson.htm taking over when current director linkurl:Julie Gerberding;http://www.cdc.gov/about/leadership/director.htm leaves the post. The Washington, D.C. rumor mill has suggested that genomicist linkurl:Francis Collins;http://www.the-scientist.com/community/posts/list/333.page may be next in line to serve as NIH director, and that Clinton-era FDA commissioner linkurl:Jane Henney;http://www.fda.gov/oc/commissioners/henney.html could return to her old post. Other names bandied about as potential FDA commissioners include another former comish, linkurl:David Kessler,;http://www.fda.gov/oc/commissioners/kessler.html and Cleveland Clinic cardiologist linkurl:Steven Nissen.;http://my.clevelandclinic.org/staff_directory/2/staff_1185.aspx
**__Related stories:__***linkurl:New NIH head talks budget, priorities;http://www.the-scientist.com/blog/display/55179/
[10th November 2008]*linkurl:FDA's 1st Chief Scientist speaks;http://www.the-scientist.com/blog/display/54555/
[16th April 2008]*linkurl:Steve Nissen goes 0 for 2;http://www.the-scientist.com/blog/display/53284/
[14th June 2007]*linkurl:Accelerating new drug development;http://www.the-scientist.com/article/display/19429/
[30th January 2001]

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham